Mining for Digital Gold: Technology Due Diligence for CIOs

How do CIOs decide which technologies to acquire and deploy? This paper presents a set of criteria used by CIOs to vet technology decisions and spread their technology bets. There is insight to be gained by defining, understanding, and applying these criteria. In fact, the more we understand the technology due diligence process the better our understanding of technology leverage becomes. Ultimately, the practice of solid due diligence processes is about the optimization of business technology. There are at least 15 criteria used by Chief Information Officers (CIOs) to perform due diligence on prospective technology investments. This paper describes these criteria and prescribes how they should be applied to technology investment decisions. CIOs benefit from a disciplined due diligence process; technology vendors also benefit since investment decision-making becomes repeatable and predictable - and therefore more manageable; and those who analyze technology decision-making benefit from disciplined due diligence which enables a systematic analysis of the drivers of technology acquisition and deployment, as well as the development of due diligence effectiveness metrics

Boards of Directors and Technology Governance: The Surprising State of the Practice

Companies spend anywhere from 1 percent to 10 percent of their gross revenues on information technology; some financial services companies actually spend much more. For a company with revenue in the $5 billion range, this could mean an annual technology expenditure of$500 million. Do boards of directors “govern” technology investments? Are they involved in major technology decisions? What role should they have in the acquisition, deployment and support of technology? The analysis reported in this document is based on a survey and follow-up interviews to more than 50 senior business technology executives. The findings reported benchmark the state of the practice—and suggest how companies can improve business technology governance. The prescriptive literature suggests that it is time for boards to assume meaningful oversight of technology investments and strategies. The data we collected (and the interviews that we conducted) support the descriptive literature: there is relatively little board involvement in technology planning or oversight. The overall conclusion is that boards of directors do not participate nearly enough in major technology decisions, are surprisingly out of the technology loop on technology issues, and are therefore missing opportunities to optimize operational and strategic technology investments. The paper ends with recommendations about the role that boards of directors should play in technology decision-making

Overdue Diligence: Questioning the Promise, Not the Premise, of Analytics

The number of emerging business technologies and the possibilities about the impact they will have on business performance seem endless. Naturally, all companies want more competitiveness and profitability. Thus, if new technology such as big data analytics can deliver superior performance, we might ask why they should not invest in data scientists, algorithms, and excellence centers. However, Gartner (2017) has reported that over 85 percent of big data analytics projects fail. A recent McKinsey survey found that only eight percent of respondent organizations have been able to scale analytics beyond limited and isolated cases (Fleming et al., 2018). We conducted a root cause analysis to examine why so many analytics projects fail. We discovered that we could group the reasons why these projects fail into at least six categories: data causes, modeling causes, tools causes, talent causes, management causes, and culture causes

Racial differences in prostate inflammation: Results from the REDUCE study

Prostate cancer (PC) risk differs between races, and we previously showed prostate inflammation in benign prostate tissue was linked with a lower future PC risk. However, whether prostate tissue inflammation varies by race is unknown. We analyzed baseline acute and chronic prostate inflammation by race in REDUCE, a 4-year, multicenter, placebo-controlled study where all men had a negative prostate biopsy prior to enrollment. We included 7,982 men with standardized central pathology review to determine the presence or absence of chronic or acute inflammation in baseline prostate biopsy tissue. Logistic regression was used to compare prostate inflammation by race, adjusting for confounders. Of 7,982 men, 7,271 were white (91.1%), 180 (2.3%) black, 131 (1.6%) Asian, 319 (4.0%) Hispanic and 81 (1%) unknown. A total of 78% had chronic and 15% had acute inflammation. On multivariable analysis relative to white men, black men were less likely (OR = 0.65, 95%CI: 0.41-1.03

Motivation and Knowledge Sharing through Social Media within Danish Organizations

Part 3: Creating Value through ApplicationsInternational audienceBased on an empirical quantitative study, this article investigates employee motivation in Danish companies and aims at determining which factors affect employees’ knowledge sharing through social media in a working environment. Our findings pinpoint towards the potential social media have for enhancing internal communication, knowledge sharing and collaboration in organizations, but the adoption is low, at this point, due to mainly organizational and individual factors. Technological factors do not seem to affect employees’ motivation for knowledge sharing as much as previous research has found, but it is the influence from the combination of individual and organizational factors, which affect the adoption of the platforms. A key finding in the study is that knowledge sharing is not a ‘social dilemma’ as previous studies have found. The study shows a positive development in employees’ willingness to share knowledge, because knowledge sharing is considered more beneficial than to hoard it

Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression

Associations between single nucleotide polymorphisms (SNPs) at 5p15 and multiple cancer types have been reported. We have previously shown evidence for a strong association between prostate cancer (PrCa) risk and rs2242652 at 5p15, intronic in the telomerase reverse transcriptase (TERT) gene that encodes TERT. To comprehensively evaluate the association between genetic variation across this region and PrCa, we performed a fine-mapping analysis by genotyping 134 SNPs using a custom Illumina iSelect array or Sequenom MassArray iPlex, followed by imputation of 1094 SNPs in 22 301 PrCa cases and 22 320 controls in The PRACTICAL consortium. Multiple stepwise logistic regression analysis identified four signals in the promoter or intronic regions of TERT that independently associated with PrCa risk. Gene expression analysis of normal prostate tissue showed evidence that SNPs within one of these regions also associated with TERT expression, providing a potential mechanism for predisposition to disease

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group

OBJECTIVES: To compare the predictive performance and potential clinical usefulness of risk calculators of the European Randomized Study of Screening for Prostate Cancer (ERSPC RC) with and without information on prostate volume. METHODS: We studied 6 cohorts (5 European and 1 US) with a total of 15,300 men, all biopsied and with pre-biopsy TRUS measurements of prostate volume. Volume was categorized into 3 categories (25, 40, and 60 cc), to reflect use of digital rectal examination (DRE) for volume assessment. Risks of prostate cancer were calculated according to a ERSPC DRE-based RC (including PSA, DRE, prior biopsy, and prostate volume) and a PSA + DRE model (including PSA, DRE, and prior biopsy). Missing data on prostate volume were completed by single imputation. Risk predictions were evaluated with respect to calibration (graphically), discrimination (AUC curve), and clinical usefulness (net benefit, graphically assessed in decision curves). RESULTS: The AUCs of the ERSPC DRE-based RC ranged from 0.61 to 0.77 and were substantially larger than the AUCs of a model based on only PSA + DRE (ranging from 0.56 to 0.72) in each of the 6 cohorts. The ERSPC DRE-based RC provided net benefit over performing a prostate biopsy on the basis of PSA and DRE outcome in five of the six cohorts. CONCLUSIONS: Identifying men at increased risk for having a biopsy detectable prostate cancer should consider multiple factors, including an estimate of prostate volume

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still do not have an approved drug to offer their patients. In this article, we outline current strategies for preventing prostate cancer in general, with a focus on the 5-α-reductase inhibitors (5-ARIs) finasteride and dutasteride. We discuss the two landmark randomized, controlled trials of finasteride and dutasteride, highlighting the controversies stemming from the results, and address the issue of 5-ARI use, including reasons why providers may be hesitant to use these agents for chemoprevention. We further discuss the recent US Food and Drug Administration ruling against the proposed new indication for dutasteride and the change to the labeling of finasteride, both of which were intended to permit physicians to use the drugs for chemoprevention. Finally, we discuss future directions for 5-ARI research

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate associations for the GSTM1 deletion (P = 4 × 10⁻¹¹) and a tag SNP for NAT2 acetylation status (P = 4 × 10⁻¹¹), and found interactions with smoking in both regions. Our findings on common variants associated with bladder cancer risk should provide new insights into the mechanisms of carcinogenesis

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.

We conducted a multi-stage, genome-wide association study of bladder cancer with a primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of European descent from five studies followed by a replication strategy, which included 8,382 cases and 48,275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3, validated previous candidate associations for the GSTM1 deletion (P = 4 × 10⁻¹¹) and a tag SNP for NAT2 acetylation status (P = 4 × 10⁻¹¹), and found interactions with smoking in both regions. Our findings on common variants associated with bladder cancer risk should provide new insights into the mechanisms of carcinogenesis